Study of a cancer-killing virus with standard treatments
Part of Cancer, Digestive system, Hormones & metabolism, Infections, Lungs & breathing, Skin clinical trials.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and able to understand and sign consent
- You can come to scheduled study visits and follow study procedures
- Your cancer is advanced and has grown (progressed) after specific prior standard treatments (varies by cancer type)
- Your body must be strong enough for treatment based on blood tests and organ function
- You must have at least one measurable tumor spot that can be biopsied and injected safely
- You have had a prior PD-1/PD-L1 immunotherapy that your cancer progressed on (with an exception for pancreatic cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
This Phase 1 study tests STI-1386, an oncolytic (tumor-fighting) virus, for solid tumors that have relapsed or do not respond to treatment. It mainly checks safety, and also looks for early signs of how well it may work.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.